



# IOF WCO-ECCEO10

May 5 – 8, 2010 • Florence, Italy

## CME EVALUATION FORM



**We encourage all participants to complete and return this evaluation form. Your opinions and recommendations are useful to us in evaluating the effectiveness of this course.**

The IOF WCO-ECCEO10 Congress has been granted accreditation by the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS – www.uems.net). EACCME credits are recognized throughout Europe and can be exchanged for national CME credits by contacting your national CME Authority. EACCME credits are also recognized by the American Medical Association (AMA) and count towards the Physician's Recognition Award (PRA). To convert EACCME credits to AMA PRA category 1 credits, please contact the AMA.

**A certificate of CME activity will be issued, after the Congress, only upon return of a completed evaluation form at the registration desk upon your departure.**

This course is designated for a maximum of 18 hours of European external CME credits. Each medical specialist will only be credited those hours that he/she actually spent in the lectures, as indicated by the boxes ticked on this Evaluation Form.



If you wish to receive credit for this activity, please complete the information below (PRINT CLEARLY) and a certificate will be mailed to you after the Congress.

Clearly PRINT or TYPE your name

Professional Degree

First Name

Family Name

Professional Address

City

State/Province

Postal Code

Country

Telephone

Fax

E-mail Address

Please rate each topic by ticking the appropriate box

## THE QUALITY OF THE CONTENT

THURSDAY, MAY 6, 2010

		EXTREMELY SATISFIED	SATISFIED	SOMEWHAT SATISFIED	SOMEWHAT UNSATISFIED	UNSATISFIED
<b>Plenary Lecture I</b> Cellular control of bone mass	SUBJECT					
	PRESENTATION					
<b>Plenary Lecture II</b> Osteoporosis, hip fractures and the biology of aging	SUBJECT					
	PRESENTATION					
<b>Meet-the-Expert Session 11:05 - 12:05</b>						
Practical approach of glucocorticoid-treated patients	SUBJECT					
	PRESENTATION					
Bone disease in primary hyperparathyroidism	SUBJECT					
	PRESENTATION					
BMU balance: Effects of antiosteoporotic agents	SUBJECT					
	PRESENTATION					
Epidemiological aspects of osteoporosis	SUBJECT					
	PRESENTATION					
Optimal dose of vitamin D	SUBJECT					
	PRESENTATION					
Assessing bone strength beyond DXA	SUBJECT					
	PRESENTATION					
Fracture healing: Can we influence it?	SUBJECT					
	PRESENTATION					
Bisphosphonates in chronic renal failure	SUBJECT					
	PRESENTATION					
Health economics and treatment selection	SUBJECT					
	PRESENTATION					
Osteoporosis in men	SUBJECT					
	PRESENTATION					
<b>Meet-the-Expert Session 14:30 - 15:30</b>						
Side effects of antifracture drugs	SUBJECT					
	PRESENTATION					
Post-fracture management	SUBJECT					
	PRESENTATION					
Vertebro/kyphoplasty	SUBJECT					
	PRESENTATION					
Pharmacogenomics	SUBJECT					
	PRESENTATION					
BMU balance: Effects of antiosteoporotic agents	SUBJECT					
	PRESENTATION					
Issues in designing and conducting clinical trials	SUBJECT					
	PRESENTATION					
Muscle and bone interaction	SUBJECT					
	PRESENTATION					
Genetics and osteoporosis: How to assess it?	SUBJECT					
	PRESENTATION					
Premenopausal osteoporosis	SUBJECT					
	PRESENTATION					
Gait and falls	SUBJECT					
	PRESENTATION					
<b>Plenary Lecture III</b> Why do bones break: Contribution of cortical and trabecular bone	SUBJECT					
	PRESENTATION					
<b>Plenary Lecture IV</b> Do men and women fracture at the same BMD?	SUBJECT					
	PRESENTATION					

		EXTREMELY SATISFIED	SATISFIED	SOMEWHAT SATISFIED	SOMEWHAT UNSATISFIED	UNSATISFIED
<b>Plenary Lecture V</b> Region specific fracture risk and response to therapy	SUBJECT					
	PRESENTATION					
<b>Plenary Lecture VI</b> Genetics of osteoporosis: What have we learnt from genome-wide association studies?	SUBJECT					
	PRESENTATION					
<b>Meet-the-Expert Session 11:05 - 12:05</b>						
Side effects of antifracture drugs	SUBJECT					
	PRESENTATION					
Post-fracture management	SUBJECT					
	PRESENTATION					
Pharmacogenomics	SUBJECT					
	PRESENTATION					
Epidemiological aspects of osteoporosis	SUBJECT					
	PRESENTATION					
Issues in designing and conducting clinical trials	SUBJECT					
	PRESENTATION					
Genetics and osteoporosis: How to assess it?	SUBJECT					
	PRESENTATION					
Premenopausal osteoporosis	SUBJECT					
	PRESENTATION					
Bisphosphonates in chronic renal failure	SUBJECT					
	PRESENTATION					
Osteoporosis in men	SUBJECT					
	PRESENTATION					
<b>Meet-the-Expert Session 14:30 - 15:30</b>						
Practical approach of glucocorticoid-treated patients	SUBJECT					
	PRESENTATION					
Bone disease in primary hyperparathyroidism	SUBJECT					
	PRESENTATION					
Vertebro/kyphoplasty	SUBJECT					
	PRESENTATION					
Optimal dose of vitamin D	SUBJECT					
	PRESENTATION					
Muscle and bone interaction	SUBJECT					
	PRESENTATION					
Assessing bone strength beyond DXA	SUBJECT					
	PRESENTATION					
Fracture healing: Can we influence it?	SUBJECT					
	PRESENTATION					
Gait and falls	SUBJECT					
	PRESENTATION					
Health economics and treatment selection	SUBJECT					
	PRESENTATION					
<b>Plenary Lecture VII</b> Interaction between bone and joints in physiology and disease	SUBJECT					
	PRESENTATION					
<b>Plenary Lecture VIII</b> Glitazone and bone: A paradigm to better understand bone physiology	SUBJECT					
	PRESENTATION					

**SATURDAY, MAY 8, 2010**

		EXTREMELY SATISFIED	SATISFIED	SOMEWHAT SATISFIED	SOMEWHAT UNSATISFIED	UNSATISFIED
<b>Plenary Lecture IX</b> Extraskeletal effects of vitamin D	SUBJECT					
	PRESENTATION					
<b>Plenary Lecture X</b> Stimulators/inhibitors of bone turnover: Together or one after the other?	SUBJECT					
	PRESENTATION					
<b>Plenary Lecture XI</b> Development plasticity and later osteoporosis	SUBJECT					
	PRESENTATION					
<b>Plenary Lecture XII</b> Emerging therapies for osteoporosis	SUBJECT					
	PRESENTATION					

**THE ORGANIZATION OF THE CONGRESS**

General organization					
Schedule (i.e., duration of presentations, time for discussions)					
Audio-Visual					
Abstract Book & Final Programme					
Exhibition					
Venue and its location					
Signage and indication to meeting rooms					
Registration (overall experience)					
Registration self check-in					
Certificate of Attendance self-printing					
Accommodation (via official agency)					

	Topics	Speakers	CME Accreditation	Chance to network	Location
Which one of the following most encouraged you to come to the Congress (rank from 1 to 5, 1 being top factor)					

**GENERAL FEELING**

	YES	NEUTRAL	NO
The pre-event information was adequate			
The event contributed to my learning			
Overall, the event met my expectations			
Did I feel the event was biased			

How did you obtain information about the congress?

- Mailing from IOF
- Mailing from ESCEO
- Someone from your company (please specify):  
\_\_\_\_\_
- Internet/Website
- Other source (please specify):  
\_\_\_\_\_

Do you plan to attend a future IOF and/or ESCEO Congress?

- Yes
- No

Do you plan to recommend a future IOF and/or ESCEO Congress to others?

- Yes
- No

Do you have any suggestions for the next IOF and/or ESCEO Congress (e.g., format, topics, etc.) or general comments?

---



---



---



---